Review of U.S. Measles Elimination Status Delayed Until November

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 4, 2026.

via HealthDay

WEDNESDAY, March 4, 2026 — An expected review of the United States’ measles elimination status has been postponed by seven months.

The meeting, originally scheduled for mid-April, will now take place in November, according to the Pan American Health Organization (PAHO), a regional branch of the World Health Organization.

Measles has been considered eliminated in the U.S. since 2000. That means the virus was no longer spreading continuously for more than one year within the country.

But large outbreaks in 2025 and early 2026 have put that status at risk.

If a major outbreak that began in West Texas on Jan. 20, 2025, is shown to be linked to others, including one now in South Carolina, the U.S. could lose its elimination status.

In January, PAHO announced it would hold a special session on April 13 to review measles data from both the U.S. and Mexico, which has also seen a deadly outbreak.

Countries must submit annual reports, and those experiencing outbreaks must provide detailed updates on how they are responding.

At the time, PAHO said the meeting date was set to give health officials “sufficient time to prepare comprehensive reports, including descriptions and analyses with detailed epidemiological and laboratory evidence.”

But that April session has now been put off until the commission’s annual meeting in November.

In an email Monday, PAHO said the delay reflects the “scope of analysis currently being undertaken by U.S. authorities, including complete virus genome sequencing and the development of a bioinformatics pipeline, alongside ongoing outbreak response efforts.”

The organization said the change is meant to “simplify and standardize the assessment process.”

In an email to CNN, Andrew Nixon, a spokesperson for the U.S. Department of Health and Human Services, said the delay does not mean the investigation is behind schedule.

The U.S. Centers for Disease Control and Prevention (CDC) appreciates PAHO’s agreement to maintain the regular verification cycle, Nixon said.

“The additional time will allow for a thorough and transparent assessment of the 2025 measles outbreaks, including comprehensive genomic sequencing and advanced analysis,” he said in an email to CNN.

"We remain committed to actively supporting current outbreak responses through laboratory testing, technical assistance, and close coordination with state and local partners," Nixon added.

Even as the review is delayed, measles cases are on the rise.

The U.S. reported more than 1,100 measles cases in the first two months of 2026. That’s roughly six times higher than has been typical for an entire year since measles was declared eliminated.

If cases continue at this pace, 2026 could surpass last year’s total of nearly 2,300 measles cases.

Though the decision on elimination status has been postponed, the timeline to be considered is unchanged. Officials will determine whether transmission continues for a full year after the start of the major outbreak: Jan. 20, 2025, in the U.S., and Feb. 1, 2025, in Mexico.

Sources

  • CNN, March, 3, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-03-05 01:43

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords